MARATTO

software · Zenodo (CERN European Organization for Nuclear Research)

Reactivity-weighted covalent natural-product screening workflow

2026Open accessLead City University

In plain language

A reproducible computational workflow prioritises covalent natural-product candidates targeting the enzymes falcipain-2 and falcipain-3. The screening pipeline combines Michael-acceptor filtering, dual recognition, covalent docking, molecular mechanics generalised Born surface area calculations, and density functional theory reactivity analyses using multiple descriptors. The released package contains a warhead-filtering cascade, retrospective enrichment benchmarks featuring property-matched and warhead-matched decoy controls, and bootstrap confidence intervals. It also provides robustness assessments covering docking-box dimensions and recognition ablation, alongside evaluations of pH sensitivity. Additional resources within the workflow include the OPT1 covalent cascade, comprehensive density functional theory reactivity data with population-scheme and basis-set cross-checks, three-dimensional covalent pose coordinates, regression test suites, and validation checksums.

Key takeaways

  • The workflow provides an in silico pipeline to screen and prioritise covalent natural products targeting falcipain-2 and falcipain-3.
  • Candidate assessment integrates Michael-acceptor filtering, dual recognition docking, MM-GBSA calculations, and multi-descriptor DFT reactivity analysis.
  • Retrospective enrichment benchmarks are supplied with property-matched and warhead-matched decoy controls alongside bootstrap confidence intervals.
  • The package includes robustness evaluations for pH sensitivity, recognition ablation, and docking-box parameters, together with regression tests and pose coordinates.

Why it matters

Evaluating covalent chemical interactions computationally requires rigorous validation across multiple physical and chemical parameters. By establishing a standardised in silico workflow that connects warhead filtering, covalent docking, and quantum-chemical reactivity analyses, this package enables researchers to consistently assess and prioritise natural products against falcipain-2 and falcipain-3 using fully cross-checked benchmarking protocols.

Commercialisation angle

This workflow serves early-stage computational drug discovery teams seeking to shortlist covalent inhibitors against falcipain-2 and falcipain-3. Because the package is entirely in silico, it sits at the initial research and discovery phase, far from clinical testing or commercial production. Pharmaceutical companies and biotechnology researchers could integrate the automated filtering cascades, DFT reactivity data, and docking protocols into their virtual screening pipelines prior to physical chemical synthesis and laboratory assays.

AI-generated from the published abstract. Always read the original work before citing.

Abstract

Reproducible in silico workflow for prioritizing covalent natural-product candidates against falcipain-2 and falcipain-3: Michael-acceptor filtering, dual recognition and covalent docking, MM-GBSA, and a multi-descriptor DFT reactivity analysis. The package includes the warhead-filtering cascade, retrospective enrichment benchmarks for falcipain-2 and falcipain-3 (property-matched and warhead-matched decoy controls, bootstrap confidence intervals), docking-box and recognition-ablation robustness checks, pH sensitivity, the OPT1 covalent cascade, DFT reactivity data with population-scheme, basis-set, and ΔSCF cross-checks, covalent pose coordinates, regression tests, and checksums.

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.5281/zenodo.22254130

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.